Susanne P. Clinch

Roche, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.

Journal: Neurology

Published: July 02, 2025

Development of a Goal Attainment Scale (GAS) outcome measure for clinical interventional studies in paediatric autism.

Development of a Goal Attainment Scale (GAS) outcome measure for clinical interventional studies in paediatric autism.

Journal: Autism : the international journal of research and practice

Published: June 25, 2025

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome using a Delphi Panel.

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome using a Delphi Panel.

Journal: medRxiv : the preprint server for health sciences

Published: April 29, 2025

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.

Journal: Neurology

Published: April 17, 2025

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome using a Delphi Panel.

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome using a Delphi Panel.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: April 05, 2025

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome Using a Delphi Panel.

Developing Meaningful Score Differences for the Bayley-4 and Vineland-3 in Angelman Syndrome Using a Delphi Panel.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: April 05, 2025

Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.

Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 18, 2025

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.

Journal: Neurology

Published: December 03, 2024

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.

Journal: Annals of clinical and translational neurology

Published: August 01, 2024

Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.

Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: August 21, 2023

Qualitative Exploration in Exit Interviews of Changes Observed in Clinical Trials for Individuals with Autism Spectrum Disorder Without Intellectual Disability.

Qualitative Exploration in Exit Interviews of Changes Observed in Clinical Trials for Individuals with Autism Spectrum Disorder Without Intellectual Disability.

Journal: Patient related outcome measures

Published: January 21, 2023

Quantitative and Qualitative Exploration of Meaningful Change on the Vineland Adaptive Behavior Scales (Vineland™-II) in Children and Adolescents with Autism Without Intellectual Disability Following Participation in a Clinical Trial.

Quantitative and Qualitative Exploration of Meaningful Change on the Vineland Adaptive Behavior Scales (Vineland™-II) in Children and Adolescents with Autism Without Intellectual Disability Following Participation in a Clinical Trial.

Journal: Patient related outcome measures

Published: January 21, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026